Eledon Pharmaceuticals (ELDN) Retained Earnings (2013 - 2026)
Eledon Pharmaceuticals (ELDN) posted Retained Earnings of -$440.2 million for Q1 2026, down 9.72% on a QoQ basis from -$401.2 million in Q4 2025, and down 21.58% year-over-year from -$561.3 million in Q1 2025.
Eledon Pharmaceuticals (ELDN) Retained Earnings (2013 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Retained Earnings history runs 14 years deep, the most recent figure standing at -$440.2 million for Q1 2026.
- Quarterly Retained Earnings fell 21.58% year-over-year to -$440.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$440.2 million (down 21.58% YoY) and the FY2025 annual result came in at -$401.2 million, down 12.83% from the prior year.
- Retained Earnings was -$440.2 million for Q1 2026 at Eledon Pharmaceuticals, down from -$401.2 million in the prior quarter.
- Across five years, Retained Earnings topped out at $9000.0 in Q3 2025 and bottomed at -$440.2 million in Q1 2026.
- A 5-year average of -$275.4 million and a median of -$311.0 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings sank 108.49% — and 2025, when it surged 100.0%.
- Eledon Pharmaceuticals' Retained Earnings stood at -$202.9 million in 2022, then plunged by 57.45% to -$319.4 million in 2023, then slipped by 11.33% to -$355.6 million in 2024, then slipped by 12.83% to -$401.2 million in 2025, then retreated by 9.72% to -$440.2 million in 2026.
- Business Quant data shows ELDN's Retained Earnings at -$440.2 million in Q1 2026, -$401.2 million in Q4 2025, and $9000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Eledon Pharmaceuticals | 403.04 Mn | 403.04 Mn | - | -440.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -440.20 Mn |
| Dec 31, 2025 | -401.20 Mn |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | -373.30 Mn |
| Mar 31, 2025 | -362.08 Mn |
| Dec 31, 2024 | -355.59 Mn |
| Sep 30, 2024 | -311.00 Mn |
| Jun 30, 2024 | -387.90 Mn |
| Mar 31, 2024 | -343.00 Mn |
| Dec 31, 2023 | -319.40 Mn |
| Sep 30, 2023 | -289.30 Mn |
| Jun 30, 2023 | -279.40 Mn |
| Mar 31, 2023 | -213.60 Mn |
| Dec 31, 2022 | -202.87 Mn |
| Sep 30, 2022 | -144.48 Mn |
| Jun 30, 2022 | -134.01 Mn |
| Mar 31, 2022 | -124.76 Mn |
| Dec 31, 2021 | -114.90 Mn |
| Sep 30, 2021 | -106.10 Mn |
| Jun 30, 2021 | -96.28 Mn |